<div><div></div><div><span><p><span>Kymera Therapeutics' Chief Executive Officer, Nello Mainolfi, has sold a total of 30,000 shares of common stock on February 25, 2026, under a Rule 10b5-1 trading plan. The transactions were executed at weighted average prices ranging from $89.78 to $93.49, resulting in a total sale amount of $2,707,812. Following these transactions, Mainolfi directly owns 666,195 shares of Kymera Therapeutics.</span></p><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Mainolfi Nello</span></td></tr><tr><td><span>Relationship</span></td><td><span>Chief Executive Officer</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$2,707,812</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><p><span>SEC Filing: </span>Kymera Therapeutics, Inc. [ KYMR ] - Form 4 - Feb. 25, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

SBIO

ARKG

KYMR

<p>Kymera Therapeutics' CEO, Nello Mainolfi, sold 30,000 shares of common stock on February 25, 2026, under a Rule 10b5-1 trading plan. The shares were sold at weighted average prices between $89.78 and $93.49, totaling $2,707,812. After the sale, Mainolfi retains ownership of 666,195 shares in the company.</p>

TradingView

iShares Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Kymera Therapeutics

Kymera Therapeutics CEO Sells 30,000 Shares